Geosmin-producing Species of Coelosphaerium (Synechococcales, Cyanobacteria) in Lake Shinji, Japan.

In Lake Shinji, Japan, periodic outbreaks of musty odour have occurred since mid-May 2007. Although the substance responsible for the odour was identified as geosmin, the odour-producing organism was unknown. We cultivated an axenic unialgal strain and determined that a species of Coelosphaerium (Synechococcales) was responsible for the production of geosmin in Lake Shinji. Our analysis was conducted using gas chromatography/mass spectrometry to determine the odorous compound. To determine the algae species, it was observed by optical microscopy to describe its morphological characteristics and the polymerase chain reaction was used to characterise the nucleotide sequence of the 16S rRNA gene and the 16S-23S rRNA internal transcribed spacer region. In addition, we explored the relationship between the number of cells of the Coelosphaerium sp. and the concentration of geosmin. In conclusion, geosmin, the cause of the musty odour in Lake Shinji in autumn 2009, was produced by Coelosphaerium sp., and to our knowledge, this is the first report of a geosmin-producing species in the family Coelosphaeriaceae.

Post-irradiation hypoxic incubation of X-irradiated MOLT-4 cells reduces apoptotic cell death by changing the intracellular redox state and modulating SAPK/JNK pathways.

To elucidate radiobiological effects of hypoxia on X-ray-induced apoptosis, MOLT-4 cells were treated under four set of conditions: (1) both X irradiation and incubation under normoxia, (2) X irradiation under hypoxia and subsequent incubation under normoxia, (3) X irradiation under normoxia and subsequent incubation under hypoxia, and (4) both X irradiation and incubation under hypoxia, and the induction of apoptosis was examined by fluorescence microscopy. About 28-33% apoptosis was observed in cells treated under conditions 1 and 2, but this value was significantly reduced to around 18-20% in cells treated under conditions 3 and 4, suggesting that post-irradiation hypoxic incubation rather than hypoxic irradiation mainly caused the reduction of apoptosis. The activation and expression of apoptosis signal-related molecules SAPK/JNK, Fas and caspase-3 were also suppressed by hypoxic incubation. Effects of hypoxic incubation were canceled when cells were treated under conditions 3 and 4 with an oxygen-mimicking hypoxic cell radiosensitizer, whereas the addition of N-acetyl-L-cysteine again reduced the induction of apoptosis. From these results it was concluded that hypoxia reduced the induction of apoptosis by changing the intracellular redox state, followed by the regulation of apoptotic signals in X-irradiated MOLT-4 cells.

Hypoxia and etanidazole alter radiation-induced apoptosis in HL60 cells but not in MOLT-4 cells.

PURPOSE: To examine how hypoxia influences ionizing irradiation-induced apoptosis in cultured mammalian cells and how a hypoxic cell radiosensitizer sensitizes apoptosis under hypoxic conditions. MATERIALS AND METHODS: Two cell lines derived from human lymphocytes, HL60 and MOLT-4, were exposed to 15 Gy X-rays under aerobic and hypoxic conditions. Etanidazole was used as a hypoxic cell radiosensitizer. The apoptotic morphological changes of nuclei and the induction of ladder-like DNA fragmentation were assessed by fluorescence microscopy and agarose gel electrophoresis, respectively. RESULTS: In HL60 cells, apototic cell death and the activation of caspases 8, 9 and 3 were less induced under the hypoxic conditions than under the aerobic ones. Treatment of hypoxic cells with etanidazole enhanced X-ray-induced apoptosis and caspase activation. However, in MOLT-4 cells, neither hypoxia nor etanidazole influenced X-ray-induced apoptosis and caspase activation. In both cell lines, the frequency of X-ray-induced DNA double-strand breaks (DSB) under hypoxia was significantly smaller than that in aerobic conditions. Treatment of hypoxic cells with etanidazole enhanced them. CONCLUSION: These results suggested that X-ray-induced apoptosis in HL60 cells was initiated by DNA DSB and the treatment of hypoxic cells with etanidazole sensitized them through the enhancement of DSB induction, whereas X-ray-induced apoptosis in MOLT-4 cells occurred through damage other than to DNA.

Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy.

A phase Ia study of a 2-nitroimidazole nucleoside analog radiosensitizer doranidazole was conducted to evaluate its toxicity and pharmacokinetics in patients undergoing conventional external beam radiotherapy. Twenty-nine patients, aged 40-74 years, with a WHO performance status of 0-2 and with adequate organ functions, were entered in the study. Single administration of doranidazole was investigated first with 13 patients and then a course of five consecutive daily administrations was tested in 16 patients. Doranidazole was given i.v. 25 min before irradiation. Doranidazole doses of 400, 800, 1300 and 2000 mg/m2 were evaluated in the former study, and daily doses of 800, 1300 and 2000 mg/m2 were investigated in the latter study. All patients tolerated doranidazole administration. Although a transient decrease in the 24-h creatinine clearance rate was observed in five patients (one in the single administration study and four in the repeat administration study), this was not considered to be the dose-limiting toxicity. Other toxicities (hematological and gastrointestinal), which may not be related to doranidazole administration, were also mild and were not dose limiting. No neurotoxicity was observed. The average maximum concentration, area under the time-concentration curve and half-life of doranidazole in serum were 172-194 microg/ml, 502-582 microg x h/l and 4.2-4.6 h, respectively, at 2000 mg/m2. At the tested doses, administration of doranidazole was tolerable and achieved serum concentrations at which reasonable radiosensitization could be expected. A phase Ib/II study to evaluate the feasibility and efficacy of up to 30 repeat administrations seems to be warranted.

Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.

BACKGROUND AND PURPOSE: A clinical study of the new 2-nitroimidazole nucleoside analogue doranidazole (PR-350) in combination with intraoperative radiotherapy is ongoing in Japan for localized unresectable pancreatic cancer. However, few data have been reported on the radiosensitivity and hypoxic fraction of human pancreatic cancers, and the efficacy of doranidazole against them. This study was undertaken to address these issues. MATERIALS AND METHODS: In vitro, four established human pancreatic cancer cell lines (SUIT-2, PANC-1, MIA PaCa-2 and BxPC-3) and murine SCCVII tumor cells (for comparison) were used. These cells were treated with 0.4 or 1 mM doranidazole for 45 mm prior to and during aerobic or hypoxic irradiation, and the cell survival was determined using the colony assay. In vivo, Balb/c nude mice bearing the pancreatic cancers (about 200 mg) on their backs received whole-body irradiation either after cervical dislocation, without physical restraint or anesthesia, or 20 min after intravenous injection of 100 mg/kg (0.4 mmol/kg) or 250 mg/kg (1 mmol/kg) of doranidazole. Following irradiation, the in vivo-in vitro assay was performed. The hypoxic fraction was estimated by the paired survival curve method. RESULTS: Regarding in vitro radiosensitivity, there were no characteristics common to the four pancreatic cancer cell lines. In vitro, doranidazole had no sensitizing effect under aerobic conditions, but under hypoxic conditions, its sensitizer enhancement ratio (SER) was 1.25-1.3 at 0. 4 mM and 1.4-1.55 at 1 mM against the four pancreatic cancer cell lines. These SERs were similar to those obtained in SCCVII cells. In vivo, the hypoxic fraction was 20% (95% CI, 11-38%) in SUIT-2, 14% (6.5-28%) in PANC-1, 10% (5.9-16%) in MIA PaCa-2, and 27% (15-46%) in BxPC-3 tumors. The SER of doranidazole was 1.15-1.3 at the dose of 100 mg/kg and 1.35-1.45 at 250 mg/kg. CONCLUSIONS: The four xenografted human pancreatic cancers had hypoxic fractions of 10-27% (mean: 18%). Doranidazole had definite in vitro and in vivo effects on all pancreatic cancer cell lines.

In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.

A new 2-nitroimidazole radiosensitizer doranidazole is now undergoing clinical evaluation in combination with intraoperative radiotherapy for unresectable pancreatic cancer. However, there have been no laboratory data on its effect against pancreatic cancer. This study was undertaken to clarify the efficacy and pharmacokinetics of doranidazole in a human pancreatic cancer SUIT-2 xenografted in the pancreas of nude mice. The tumor-bearing mice were irradiated to the upper abdomen using electron beams with or without prior administration of doranidazole. The tumors were excised 3-6 days later and their weight was measured. Doranidazole given alone had no antitumor effect, but it had radiosensitizing effects when 100, 150, or 200 mg/kg of the drug was combined with single 5 Gy irradiation. The tumor/serum ratios for doranidazole concentration were 0.3-0.4, but the concentrations in the tumor were similar to those in the surrounding normal pancreas. At doses of 100 mg/kg or higher, concentrations of doranidazole in the pancreatic tumor appeared to be sufficient to obtain definite radiosensitization.

Neural discriminant analysis.

In this article the role of the bootstrap is highlighted for nonlinear discriminant analysis using a feedforward neural network model. Statistical techniques are formulated in terms of the principle of the likelihood of a neural-network model when the data consist of ungrouped binary responses and a set of predictor variables. We illustrate that the information criterion based on the bootstrap method is shown to be favorable when selecting the optimum number of hidden units for a neural-network model. In order to summarize the measure of goodness-of-fit, the deviance on fitting a neural-network model to binary response data can be bootstrapped. We also provide the bootstrap estimates of the biases of excess error in a prediction rule constructed by fitting to the training sample in the neural network model. We additionally propose bootstrap methods for the analysis of residuals in order to identify outliers and examine distributional assumptions in neural-network model fitting. These methods are illustrated through the analyzes of medical diagnostic data.

[Pharmacological analysis of atypical beta-adrenoceptors in the guinea pig gastrointestinal tissue systems].

The purpose of the present study was to characterize the atypical beta-adrenoceptors involved in relaxant responses in guinea pig gastric fundus, duodenum and ileum in functional experiments with catecholamines (isoprenaline, noradrenaline and adrenaline), beta 3-adrenoceptor agonists (BRL37344 and CGP12177A) and a non-selective beta 1-, beta 2- and beta 3-adrenoceptor antagonist bupranolol, and to obtain further evidence to clarify whether there is a tissue difference in atypical beta-adrenoceptors in the guinea pig gastrointestinal tissue systems. The atypical beta-adrenoceptors are present in gastric fundus, duodenum and ileum of guinea pig. In the presence of propranolol (1 microM) or atenolol (100 microM) plus butoxamine (100 microM), bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for catecholamines and beta 3-adrenoceptor agonists. There was not a significant difference of pA2 values for bupranolol against these agonists between gastric fundus, duodenum and ileum of guinea pig. These results suggest that guinea pig gastric fundus, duodenum and ileum relaxation are mediated predominantly by an atypical beta-adrenoceptor population whereas the classical beta 1- or/and beta 2-adrenoceptors play a subordinate function role and that the receptors of three tissues are pharmacological identified by functional approaches. There is not a tissue difference in atypical beta-adrenoceptors in the guinea pig gastrointestinal tissue systems between stomach and ileum.

Effects of LP-805, a newly developed vasodilator, on myocardial metabolism in ischaemic dog hearts.

The effects of LP-805, a newly developed vasodilator, on changes in the myocardial energy and carbohydrate metabolism induced by ischaemia were studied in open-chest anaesthetized dogs. Ischaemia was induced by ligating the left anterior descending coronary artery for 3 min. The myocardial energy stores were depleted, and the levels of glycolytic intermediates were altered 3 min after the onset of ischaemia. Energy change potential was decreased, and ([G6P] + [F6P])/[FDP] and [lactate]/[pyruvate] ratios were increased by ischaemia. These findings indicated that the myocardial metabolism was converted from an aerobic to an anaerobic type by ischaemia. LP-805 (10, 30, or 100 micrograms kg-1) was injected intravenously 5 min before the onset of ischaemia. LP-805 prevented the myocardial energy depletion and alterations of myocardial carbohydrate metabolism due to ischaemia, indicating that it appeared to convert the anaerobic metabolism back to aerobic metabolism in the ischaemic myocardium. In conclusion, LP-805 may reduce the ischaemic influence on the myocardium.

Endothelium-dependent vasodilation by LP-805, a novel vasodilating agent, on rat thoracic aorta.

1. In rat aortae with [E(+)-tissue] and without [E(-)-tissue] intact endothelium, LP-805 relaxed the preparations precontracted with 35.9 mM K+ and its action in E(+)-tissues was more potent than that in E(-)-tissues. Moreover, the inhibitory action of glibenclamide in E(-)-tissues was more potent than that in E(+)-tissues. 2. The relaxing action of LP-805 on E(+)-tissues treated with NG-nitro-L-arginine methyl ester (10 microM), a potent inhibitor of nitric oxide synthesis, was the same as that in E(-)-tissues. 3. Methylene blue (10 microM) also inhibited the LP-805 induced relaxation in E(+)-tissues. 4. Indomethacin (10 microM) had no effect on LP-805-induced relaxation in E(+)-tissues. 5. These results suggest that the vasorelaxant action of LP-805 involves the mechanism which causes the release of nitric oxide (NO) from vascular endothelium.

Effects of LP-805, a novel vasorelaxant agent, a potassium channel opener, on rat thoracic aorta.

1. In rat thoracic aorta, LP-805 (0.1-10 microM) caused the marked reduction of NE-induced maximum response and relaxed the low K+ (less than 35.9 mM)-induced contraction, in a concentration-dependent manner, but failed to relax the high K+ (65.9 mM)-induced contraction. 2. Glibenclamide (0.3-1 microM) caused a parallel shift of concentration-response curve produced by LP-805 for 25.9 mM K(+)-induced contraction and prevented the LP-805-induced reduction in maximum response evoked by NE in a concentration-dependent manner. 3. Glibenclamide (10 microM) prevented the LP-805 (10 microM)-induced decrease in cytosolic Ca2+ levels which was increased by 1 microM NE or 25.9 mM K+. 4. LP-805 (10 microM) increased basal 86Rb efflux, which was completely inhibited by 10 microM glibenclamide. 5. The results suggest that LP-805 causes a vasorelaxation as a consequence of the decrease in cytosolic Ca2+ levels due to the increase in K+ efflux via opening ATP-dependent K+ channels.

Effects of LP-805, a new vasodilating agent, on cytosolic Ca2+ and contraction in vascular smooth muscle of rat aorta.

1. LP-805 (0.1-10 microM) caused the reduction in norepinephrine (NE)-and serotonin (5-HT)-induced maximum response, a parallel shift of the concentration-response curve for prostaglandin F2 alpha (PGF2 alpha), in a concentration-dependent manner, but not K(+)-induced maximum response. 2. In Ca(2+)-free solution, LP-805 (0.1-10 microM) markedly inhibited the phasic contraction induced by 0.3 microM NE and the contraction induced by Ca2+ (0.1-2 mM) in the presence of 0.3 microM NE, in a concentration-dependent manner. Similar results were obtained in the presence of 5-HT (10 microM) or PGF2 alpha (10 microM). 3. In fura-2 loaded strips, ryanodine (10 microM) and LP-805 (10 microM) abolished 1 microM NE- and 30 microM 5-HT-induced phasic contractions, and inhibited the increase in cytosolic Ca2+ levels by both the agonists in the absence of external Ca2+, but had no influence on the following sustained contractions. 4. The effects of LP-805 on PGF2 alpha-induced Ca2+ transient and large sustained contraction were similar to those of ryanodine. 5. These results suggest that a vasodilatory effect of LP-805 might account for inhibiting the mobilization of external Ca2+ through receptor mediated passway and the Ca2+ release from a ryanodine sensitive Ca2+ store.

Effects of LP-805, a new vasodilating agent, on rat thoracic aorta.

1. In canine coronary arteries, the contraction induced by prostaglandin F2 alpha (PGF2 alpha), but not by 65.9 mM K+, were relaxed by LP-805 (0.01-10 microM) in a concentration-dependent manner. 2. In rat thoracic aorta, LP-805 (0.1-10 microM) also relaxed the preparations contracted with norepinephrine (NE) and PGF2 alpha, but did not relax the contraction produced by 65.9 mM K+. 3. LP-805 (3-10 microM) inhibited the increase in cytosolic Ca2+ levels and contractions evoked by NE (1 microM) in the absence or presence of external Ca2+ in rat thoracic aorta. 4. LP-805 (0.1-10 microM) inhibited synthesis of IP3 induced by NE (0.3 microM) and cyclic AMP phosphodiesterase activity, and increased intracellular cyclic AMP levels in rat thoracic aorta. 5. These results suggest that a vasodilatory effect of LP-805 is due to inhibiting the increase in cytosolic Ca2+ levels via stimulation of various receptors, modulating second messenger synthesis.

Attenuation of ischemia-induced regional myocardial acidosis by LP-805, a newly developed vasodilator, in dogs.

The effect of 8-tert-butyl-6,7-dihydropyrrolo[3,2-e]-5-methyl- pyrazolo[1,5-a]pyrimidine-3-carbonitrile (LP-805), a newly developed vasodilator, on myocardial acidosis induced by ischemia was studied in anesthetized open-chest dogs. Ischemia was induced by partially occluding the left anterior descending coronary artery. The coronary flow was artificially reduced to about 1/3 of the original flow. Myocardial pH was measured with a glass micro pH electrode inserted into the left ventricular wall perfused by the occluded artery. Myocardial pH decreased from about 7.5 to about 6.9 after the onset of ischemia and remained at this low level until the occluded coronary artery was released. After 30 min of ischemia, either saline containing 0.1 N HCl or 10, 30 or 100 micrograms/kg of LP-805 was injected intravenously. LP-805 attenuated the decrease in myocardial pH induced by ischemia in a dose-dependent manner. In conclusion, LP-805 may reduce the influence of ischemia on the myocardium.

Residual plots for log odds ratio regression models.

This article describes graphical diagnostic methods for log odds ratio regression models. To study the effects of an additional covariate on log odds ratio regression analysis, three types of residual plots based on weighted least squares (WLS) are discussed: (i) added variable plot (partial regression plot), (ii) partial residual plot, and (iii) augmented partial residual plot. These plots provide diagnostic procedures for identifying heterogeneity of error variances, outliers, or nonlinearity of the model. They are especially useful for clarifying whether including a covariate as a linear term is appropriate, or whether quadratic or other nonlinear transformations are preferable. A well-known data set for case-control studies is analyzed to illustrate the residual plots.

Pentylenetetrazole suppresses the potassium current in Euhadra neurons which is coupled with Ca2+/calmodulin-dependent protein phosphorylation.

The Ca2+/calmodulin-dependent protein phosphorylation-related mechanism underlying pentylenetetrazole (PTZ)-induced reduction of delayed potassium current (IKD) was examined in identified Euhadra neurons. PTZ gradually reduced peak IKD in a dose-dependent manner, as well as an inhibition of Ca2+/calmodulin-dependent protein phosphorylation. Similar effects were observed by a general protein kinase inhibitor, 1-(5-isoquinolinylsulfonyl)-2-methylpoperazine, whose saturating dose occluded the action of PTZ on the IKD. Intracellular injection of Ca2+/calmodulin-dependent protein kinase II transiently restored the PTZ-suppressed IKD nearly to the pre-PTZ level, whereas either CaCl2 or calmodulin, injected in the same way, had little effect. However, this restoration was not detectable in the presence of N-(6-aminohexyl)-5-chloronaphthalenesulfonamide, a calmodulin inhibitor, in the perfusate. These results suggest that PTZ suppresses the potassium current coupled with Ca2+/calmodulin-dependent protein phosphorylation.

Effect of potassium gluconate on potassium transport of rat erythrocytes.

Effect of potassium gluconate (K-GL) on K+ uptake of rat erythrocytes was investigated. K-GL produced a significant increase in active K+ transport of Na+-rich erythrocytes, while Na+,K+-ATPase activity of hemoglobin-free ghosts without a glycolytic system was unaffected. When the experiment was carried out in intact erythrocytes, K-GL increased the lactate production and ATP content, and it promoted the methemoglobin reduction rate. In Na+-rich erythrocytes, the glycolysis inhibitors which produced a marked reduction in lactate content abolished the K-GL-induced increase in K+ and ATP content without affecting the KCl-induced increase. These results suggest that K-GL enhances K+ transport of erythrocytes through acceleration of glycolytic process.

[Comparative studies of the therapeutic effect of colistin methanesulfonate administered intramuscularly and intravenously on the acute bacterial infection in mice (author's transl)].

The therapeutic potencies of colistin methanesulfonate (CLM) was assessed quantitatively in acute infection of mice with clinically isolated strains of Escherichia coli and Pseudomonas aeruginosa, and effect of different routes of administration was compared. There was no detectable difference in the therapeutic effect of CLM when intramuscular (im) or intravenous (iv) administration was initiated one hour after the infection. On the other hand, a significant difference in ED50 given by im and iv administrations was observed, indicating the superiority of iv administration, when the treatment started 4 to approximately hours after the infection. No difference in the therapeutic effect of polymyxin B (PMB) and tetracycline (TC) administered via either im or iv route was found even in the delayed administration. In contrast to PMB and TC, lower toxicity of CLM was determined when it was administered iv rather than im.